Investor FAQs


Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.

Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer™), investigator benchmarking and budgeting (Medidata Grants Manager™), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor™), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave®).

Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.

Medidata Solutions was founded in 1999

The Company's initial public offering (IPO) was on June 25, 2009 at a price of $14.00 per share.

The Company's common stock trades under the stock symbol MDSO.

The Company's shares are listed on NASDAQ Global Market.

Medidata had approximately 59.8 million shares of common stock outstanding as of June 30, 2017.

350 Hudson Street, 9th Floor

New York, NY 10014

(212) 918 - 1800

As of June 30, 2017, Medidata Solutions had 1,595 employees and total headcount of over 1,970 including additional non-employee contractors.

The Company's common stock can be purchased or sold through any stock brokerage or discount brokerage firm.

The Company does not offer a direct share purchase plan.

The Company does not issue dividends or have a DRIP program at this time.

You can access the Company's press releases, annual reports, quarterly reports and other materials online at

Our Transfer Agent, American Stock Transfer & Trust Company, can help you in a variety of shareowner-related services including change of address, lost stock certificates, stock transfer, account status and other administrative services. You can write or call our Transfer Agent at:

American Stock Transfer and Trust

Attn: Shareholder Services

6201 15th Avenue

Brooklyn, NY 11219

(888) 257-7340

You may also access our transfer agent over the Internet at You can check your account balances, access certain shareholder services, and obtain various forms and other helpful information you may need online.

Shareowners wishing to transfer their stock should send their written request, stock certificate(s) and other required documentation to:

American Stock Transfer and Trust

Attn: Shareholder Services

6201 15th Avenue

Brooklyn, NY 11219

SEC documents can be accessed under "SEC filings" at or at

Information regarding the timing of quarterly earnings releases and webcasts is available in the Event Calendar as well as detailed in specific press releases available in the News Section of the corporate Website.

Deloitte & Touche LLP

A copy of the final initial public offering prospectus can be obtained at

Please submit your question using the form below.

* Indicates required field

Stock Quote

  • 76.55 Price:
  • 0.24 Change:
  • 77.07 Day High:
  • 75.94 Day Low:
  • 663,826 Volume:

Investor Contact

Anthony D'Amico
Senior Director, Investor Relations
+1 732 767 4331